Anticoagulation of cancer patients with non-valvular atrial fibrillation receiving chemotherapy
Approximately 4% of cancer patients have non-valvular atrial fibrillation (NVAF) and require anticoagulation for...
Trials and Therapy
DOACs in the treatment of cancer-associated thrombosis
Since the publication of the SELECT-D trial1 and the Hokusai-VTE Cancer study2, there has been a shift in the...
An update on the status of direct oral anticoagulants in children
Introduction Once considered a condition of adults or the elderly, venous thromboembolism (VTE) is now being recognized...
The safety of DOACs to treat VTE in patients with brain tumors
Patients with primary and metastatic brain tumors have a high risk of venous thromboembolism (VTE), occurring in 20-30%...
A talking point for the CANTOS trial
A year after the results of the CANTOS trial were first presented, they were still an important talking point at ESC...
Lessons from the CATCH study: beware of the risk of bleeding in neoplastic patients treated for VTE
The results of an interesting secondary analysis of the CATCH study were published recently and they are useful for a...
Rapping about new anticoagulants for CAT at ICTHIC 2018
Rapping about new anticoagulants for CAT at ICTHIC 2018 Cancer patients are four or five times as likely to develop...
Anticoagulant treatment in patients with thrombocytopenia and cancer-associated thrombosis
One of the most complex situations in the treatment of cancer-associated thrombosis is represented by oncological...
The conundrum of anti-angiogenesis in cancer
“Anti-angiogenesis in cancer is something of a conundrum where the unexpected is to be expected.”...
CAT Studies
The following list contains a selection of the most recent clinical trials about cancer-associated thrombosis....